Clinical trial
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or…
NCT00445198 · AbbVie (prior sponsor, Abbott), Industry · Completed
Key facts
| NCT number | NCT00445198 |
|---|---|
| Title | A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies |
| Official title | A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies |
| Lead sponsor | AbbVie (prior sponsor, Abbott), Industry |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Small Cell Lung Cancer, Small Cell Lung Carcinoma |
| Intervention type | Drug |
| Interventions | ABT-263 |
| Enrollment | 86 |
| Start date | Apr 1, 2007 |
| Primary completion | Dec 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | Mar 8, 2007 |
| Last update posted | Jun 6, 2018 |
| Countries | Canada, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: